With the birth of PCSK9 and clinical practice, more and more studies are focusing on patients achieving optimal LDL-C levels and finding that residual cardiovascular risk will be increased if these patients have combined dyslipidemia, particularly for low HDL-C concentrations and high TG levels [22]. The gene discussed is PCSK9; the disease is metabolic syndrome.